|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
H05AA02
|
|
gptkbp:brand
|
Forteo
Forsteo
|
|
gptkbp:CASNumber
|
52232-67-4
|
|
gptkbp:category
|
parathyroid hormone analog
anabolic agent for bone
bone formation agent
|
|
gptkbp:chemicalFormula
|
C181H291N55O51S2
|
|
gptkbp:contraindication
|
gptkb:hypercalcemia
gptkb:Paget's_disease
bone metastases
unexplained elevations of alkaline phosphatase
prior radiation therapy involving the skeleton
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
about 1 hour
|
|
gptkbp:KEGGID
|
D06053
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:maximumDurationOfUse
|
2 years
|
|
gptkbp:mechanismOfAction
|
gptkb:parathyroid_hormone_receptor_agonist
stimulates osteoblast activity
|
|
gptkbp:notRecommendedFor
|
adolescents
children
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
patients at high risk of fracture
|
|
gptkbp:proteinSequence
|
first 34 amino acids of human parathyroid hormone
|
|
gptkbp:PubChem_CID
|
16129668
DB06285
|
|
gptkbp:riskFactor
|
osteosarcoma (in animal studies)
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:hypercalcemia
nausea
dizziness
leg cramps
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:UNII
|
Q7Z4601902
|
|
gptkbp:usedFor
|
gptkb:bone
glucocorticoid-induced osteoporosis
treatment of osteoporosis in men
treatment of osteoporosis in postmenopausal women
|
|
gptkbp:bfsParent
|
gptkb:parathyroid_hormone
gptkb:テリパラチド
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
teriparatide
|